低剂量甲氨蝶呤长期治疗中用药错误相关中毒的预测因素
本研究回顾性分析41例非肿瘤门诊患者首次使用低剂量甲氨蝶呤(MTX)因用药错误导致中毒的病例,其中36例将每周给药误为每日给药,5例误将MTX当作甲基麦角新碱。29例(70.7%)出现临床症状,年龄、总剂量和用药天数可预测症状发生,所有患者经亚叶酸治疗均完全康复。
要点
- 首次处方MTX时需明确告知患者每周给药方案以避免用药错误
- 年龄、总剂量和用药天数是症状出现的预测因素
- 无症状患者接受亚叶酸30 mg/m2/天治疗5天,所有患者完全康复
核心结论
- 年龄、总剂量和用药天数是MTX用药错误后出现临床症状的预测因素。
- 所有患者经亚叶酸治疗均完全康复,无患者使用 glucarpidase。
研究设计与样本
- 回顾性观察性研究,纳入2008年7月至2020年3月非肿瘤门诊中MTX用药错误的病例,共41例。
主要发现
- 41例中36例每日服用MTX而非每周,5例误将MTX当作甲基麦角新碱。
- 12/41例(29.3%)无症状,29例(70.7%)出现皮肤、血液和胃肠道症状。
- 有症状患者年龄更大、总剂量更高、用药时间更长。
- 无症状患者接受亚叶酸30 mg/m2/天治疗5天。
关键数值与推荐
- 有症状患者接受亚叶酸联合针对具体临床表现的治疗。
- 无症状患者亚叶酸剂量为30 mg/m2/天,共5天。
临床怎么用
- 首次处方MTX时应与患者充分沟通,避免用药错误。
- 综合评估年龄、总剂量和用药天数以识别需要最大起始亚叶酸治疗和更密切监测的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To study the predictive factors for the development of clinical manifestations in poisoning due to the erroneous taking of low-dose methotrexate (MTX). METHODS: A retrospective observational study was performed. Only cases of erroneous administration in non-oncologic outpatients were included (July 2008-March 2020). RESULTS: Forty-one cases were included. All patients were taking MTX for the first time. In 36 cases, patients took MTX daily instead of weekly. In the other five patients, MTX was sold instead of methylergometrine. Clinical manifestations were absent in 12/41 patients (29.3%). All 29 (70.7%) symptomatic patients recognized the medication error when they developed clinical manifestations: dermatological, haematological and gastrointestinal symptoms. Statistical results showed that symptomatic patients were older, received a higher amount of total dose and were treated for longer. Moreover, the probability of being symptomatic increases as a function of age and of total dose. Asymptomatic patients were treated with folinic acid (30 mg/m2 /day) for 5 days. Symptomatic patients were treated with folinic acid together with treatments for the specific clinical manifestations. No patients were treated with glucarpidase. All patients fully recovered. CONCLUSIONS: When MTX is prescribed for the first time, it is important to clearly communicate with patients to avoid therapeutic errors. In our experience, age, total dose taken and number of days of assumption are predictive for the presence/absence of clinical manifestations. These parameters must be evaluated together to identify patients needing maximum starting treatment with folinic acid and closer monitoring.
引用
- Schicchi A, Scaravaggi G, Petrolini VM, et al. Poisoning related to therapeutic error in prolonged low-dose methotrexate treatment. Br J Clin Pharmacol. 2020. PMID: 33179288. doi:10.1111/bcp.14652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。